FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213305983> ?p ?o ?g. }

• W4213305983 endingPage "1369" @default.
• W4213305983 startingPage "1363" @default.
• W4213305983 abstract "Background: GV1001 is a human telomerase peptide vaccine that induces a CD4/CD8 T-cell response against cancer cells, thereby affording an immunological anti-tumor effect. Here, we evaluated the efficacy and safety of GV1001 in combination with chemotherapy in patients with metastatic colorectal cancer who had failed first-line chemotherapy. Methods: This multicenter, non-randomized, single-arm phase II study recruited recurrent or metastatic colorectal cancer patients with measurable disease who had failed first-line chemotherapy. Patients received GV1001 and chemotherapy concomitantly based on a pre-established schedule. Cytotoxic chemotherapy and targeted agents (bevacizumab, cetuximab, or aflibercept) were allowed to be used at the discretion of the investigator. The primary endpoint was the disease control rate; secondary endpoints were the objective response rate, progression-free survival, overall survival, and safety outcomes. The baseline serum eotaxin level (a potential predictive biomarker of GV1001) was analyzed. To determine whether an adequate immune response had been induced, a delayed-type hypersensitivity test and a T-cell proliferation test were performed. Results: From May 13, 2015 to October 13, 2020, 56 patients with recurrent or metastatic colorectal cancer treated in seven hospitals of South Korea were enrolled. The median patient age was 64 years (range, 29-82 years); 67.9% were men. Of all patients, 66.1% had left-side colorectal cancer and the RAS mutation was present in 25%. The disease control rate and the objective response rates were 90.9% (95% confidence interval [CI]: 82.4-99.4%) and 34.1% (95% CI, 20.1-48.1%), respectively. The median progression-free survival was 7.1 months (95% CI, 5.2-9.1 months) and the median overall survival was 12.8 months (95% CI, 9.9-15.8 months). The most common all-grade adverse events were neutropenia (48.2%), nausea (26.8%), neuropathy (25.0%), stomatitis (21.4%), and diarrhea (21.4%). Immune response analysis showed that no patient had positive delayed-type hypersensitivity test results; antigen-specific T-cell proliferation was observed in only 28% of patients. The baseline eotaxin level was not associated with any efficacy outcome. Conclusion: Although no clear GV1001-specific immune response was observed, the addition of GV1001 vaccination to chemotherapy was tolerable and associated with modest efficacy outcomes." @default.
• W4213305983 created "2022-02-24" @default.
• W4213305983 creator A5011928803 @default.
• W4213305983 creator A5018855985 @default.
• W4213305983 creator A5024123838 @default.
• W4213305983 creator A5033087588 @default.
• W4213305983 creator A5034731588 @default.
• W4213305983 creator A5041482904 @default.
• W4213305983 creator A5041556537 @default.
• W4213305983 creator A5044201544 @default.
• W4213305983 creator A5069818368 @default.
• W4213305983 creator A5082124715 @default.
• W4213305983 creator A5084870834 @default.
• W4213305983 creator A5084955195 @default.
• W4213305983 creator A5091240913 @default.
• W4213305983 date "2022-01-01" @default.
• W4213305983 modified "2023-10-11" @default.
• W4213305983 title "A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer" @default.
• W4213305983 cites W137218829 @default.
• W4213305983 cites W1940241680 @default.
• W4213305983 cites W1986986419 @default.
• W4213305983 cites W1990467165 @default.
• W4213305983 cites W1991098068 @default.
• W4213305983 cites W1993934102 @default.
• W4213305983 cites W2000856540 @default.
• W4213305983 cites W2023843355 @default.
• W4213305983 cites W2036112796 @default.
• W4213305983 cites W2044606083 @default.
• W4213305983 cites W2045402712 @default.
• W4213305983 cites W2046555621 @default.
• W4213305983 cites W2064507032 @default.
• W4213305983 cites W2074516592 @default.
• W4213305983 cites W2079691060 @default.
• W4213305983 cites W2081022234 @default.
• W4213305983 cites W2092246818 @default.
• W4213305983 cites W2096176330 @default.
• W4213305983 cites W2101965993 @default.
• W4213305983 cites W2110108910 @default.
• W4213305983 cites W2115735904 @default.
• W4213305983 cites W2121436255 @default.
• W4213305983 cites W2134403422 @default.
• W4213305983 cites W2136293754 @default.
• W4213305983 cites W2140251048 @default.
• W4213305983 cites W2148219862 @default.
• W4213305983 cites W2153876458 @default.
• W4213305983 cites W2164154441 @default.
• W4213305983 cites W2889646458 @default.
• W4213305983 cites W2898109351 @default.
• W4213305983 doi "https://doi.org/10.7150/jca.70385" @default.
• W4213305983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35281880" @default.
• W4213305983 hasPublicationYear "2022" @default.
• W4213305983 type Work @default.
• W4213305983 citedByCount "3" @default.
• W4213305983 countsByYear W42133059832022 @default.
• W4213305983 countsByYear W42133059832023 @default.
• W4213305983 crossrefType "journal-article" @default.
• W4213305983 hasAuthorship W4213305983A5011928803 @default.
• W4213305983 hasAuthorship W4213305983A5018855985 @default.
• W4213305983 hasAuthorship W4213305983A5024123838 @default.
• W4213305983 hasAuthorship W4213305983A5033087588 @default.
• W4213305983 hasAuthorship W4213305983A5034731588 @default.
• W4213305983 hasAuthorship W4213305983A5041482904 @default.
• W4213305983 hasAuthorship W4213305983A5041556537 @default.
• W4213305983 hasAuthorship W4213305983A5044201544 @default.
• W4213305983 hasAuthorship W4213305983A5069818368 @default.
• W4213305983 hasAuthorship W4213305983A5082124715 @default.
• W4213305983 hasAuthorship W4213305983A5084870834 @default.
• W4213305983 hasAuthorship W4213305983A5084955195 @default.
• W4213305983 hasAuthorship W4213305983A5091240913 @default.
• W4213305983 hasBestOaLocation W42133059831 @default.
• W4213305983 hasConcept C121608353 @default.
• W4213305983 hasConcept C126322002 @default.
• W4213305983 hasConcept C143998085 @default.
• W4213305983 hasConcept C203014093 @default.
• W4213305983 hasConcept C203092338 @default.
• W4213305983 hasConcept C2776694085 @default.
• W4213305983 hasConcept C2777802072 @default.
• W4213305983 hasConcept C2779998722 @default.
• W4213305983 hasConcept C526805850 @default.
• W4213305983 hasConcept C535046627 @default.
• W4213305983 hasConcept C71924100 @default.
• W4213305983 hasConceptScore W4213305983C121608353 @default.
• W4213305983 hasConceptScore W4213305983C126322002 @default.
• W4213305983 hasConceptScore W4213305983C143998085 @default.
• W4213305983 hasConceptScore W4213305983C203014093 @default.
• W4213305983 hasConceptScore W4213305983C203092338 @default.
• W4213305983 hasConceptScore W4213305983C2776694085 @default.
• W4213305983 hasConceptScore W4213305983C2777802072 @default.
• W4213305983 hasConceptScore W4213305983C2779998722 @default.
• W4213305983 hasConceptScore W4213305983C526805850 @default.
• W4213305983 hasConceptScore W4213305983C535046627 @default.
• W4213305983 hasConceptScore W4213305983C71924100 @default.
• W4213305983 hasIssue "4" @default.
• W4213305983 hasLocation W42133059831 @default.
• W4213305983 hasLocation W42133059832 @default.
• W4213305983 hasLocation W42133059833 @default.
• W4213305983 hasOpenAccess W4213305983 @default.
• W4213305983 hasPrimaryLocation W42133059831 @default.

• next